Elasty Grand Plus – Lido is a cross-linked hyaluronic acid filler that is developed by Dongbang Medical in South Korea. This filler is excellent for treating facial deep wrinkles and can be used on the nose, the chin, the forehead, or any other area of the face. The subcutaneous and periosteal layers of the skin are where the injections for Elasty Grand Plus Lido should be administered. There is also Elasty Fine, Elasty Fine Plus, Elasty Deep, Elasty Grand, and Elasty Deep Plus Lido. These are the other items.
As a result of its utilization of Low Crosslinking Technology and Thin Layer Washing Technology, the HA filler known as Elasty Grand Plus – Lido is a filler that maximizes both the ease of operation and the level of safety it provides. The LC Technology maintains the intrinsic safety and efficacy of HA by using a little quantity of crosslinking agent, which minimizes the amount of HA that is deformed as a result of the process. In order to improve the product’s level of safety, the TLW Technology gets rid of the by-products that are formed during the crosslinking process.
Benefits of Elasty Grand Plus with Lidocaine:
- Low crosslinking technology
- Thin layer washing technology
- High viscoelasticity
- Little post swelling
- Safe Supplied in a glass syringe
Purpose of product usage: The lotion can be used to the forehead, nose, and chin, as well as deep wrinkles on the face.
Package: 2 syringe/ 1.0mL (cross-linked hyaluronic acid gel with Lidocaine 24mg/mL), 4 disposable needles (2x 27G1/2”, 2x 30G1/2”)
Storage conditions: Shelf life is 24 months from manufacturing date
Keep away from direct sunlight Store at room temperature (1-30°C)
Please be aware that our products are intended to be used only under the supervision of a qualified medical expert. We cannot be held liable for any adverse effects that may be caused by the use of our goods by those who are not trained medical professionals. We will not provide compensation for products that have been squandered or used inappropriately.
Reviews
There are no reviews yet.